ALT Altimmune Inc

25,790

$4.63

$1.06

(29.69%)

Today

Watchers	25,790
52-Wk Low	$2.09
52-Wk High	$17.17

Market Cap	$191.81M
Volume (M)	346,292.00
52-Wk High	$17.17
52-Wk Low	$2.09

Fundamentals

Altimmune (ALT, $3.56) price may drop as it broke higher Bollinger Band on Dec 01, 2023Tickeron - Stocks • 3 days ago

This price move could be a signal that ALT may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Share to Feed

Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades LowerBenzinga • 4 days ago

Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide read more...

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of PemvidutideGlobe Newswire • 5 days ago

Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatmentOver 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at...

Altimmune (ALT, $3.06) RSI Indicator left the overbought zone on November 27, 2023Tickeron - Stocks • 7 days ago

This is a signal that ALT's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and SurModics (SRDX)TipRanks Financial Blog • 27 days ago

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT Research Report) and SurModics (SRD...

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business UpdateGlobe Newswire • 28 days ago

Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line...

Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Altimmune (ALT)TipRanks Financial Blog • about 1 month ago

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seagen (SGEN Research Report) and Altimmune (ALT...

Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023Globe Newswire • about 1 month ago

GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial...

Altimmune granted Fast Track designation by FDA for pemvidutideThe Fly • about 1 month ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)Globe Newswire • about 1 month ago

GAITHERSBURG, Md., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...